K. P. Papadopoulos, “Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study”, J of Skin, vol. 2, no. S1, p. S45, Feb. 2018.